ArticleScientific reports2026
Gallic acid chemoprevention of oral carcinogenesis is associated with HSD11β2 upregulation and immune remodeling.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Naturally derived phytochemicals such as gallic acid (GA) exhibit multitargeted anticancer properties and favorable safety profiles, yet the molecular mechanisms underlying their chemopreventive effects in head and neck squamous cell carcinoma (HNSCC) remain incompletely defined. Using a 4-nitroquinoline-1-oxide (4NQO)-induced oral carcinogenesis mouse model, we evaluated GA's effects on tumor progression, immune modulation, and stress-hormone-related pathways. Phenotypic outcomes were assessed by histopathology, proliferation markers, and in vitro cytotoxicity assays. Transcriptomic changes were profiled by RNA sequencing, pathway enrichment and validation using RT-qPCR, Western blotting, ELISA, and flow cytometry. GA selectively inhibited proliferation of HNSCC cell lines (CAL27, SCC83) while sparing normal oral epithelial cells (TE1177). In vivo, GA reduced tumor burden and histopathologic severity without affecting body weight. RNA-seq analysis revealed coordinated modulation of immune and stress-response pathways, including upregulation of Carmil2, Cd27, and Cd209d and downregulation of Fos, Pappa, and Hif1a. GA increased HSD11β2 expression in vitro and in vivo and reduced cortisol in cAMP-stimulated HNSCC cells, findings consistent with reduced local glucocorticoid signaling. GA also increased IL-2 and decreased IL-10 in T cells, reduced monocytic MDSCs, and lowered PD-L1 on pro-inflammatory macrophages. Together, these findings identify HSD11β2/glucocorticoid metabolism as a potential axis associated with GA-mediated oral cancer chemoprevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.